Pharmaceutical Usage Trends Before and After Bariatric Surgery: Population-Based Cohort Study

Overview

This population-based cohort study from Lombardy, Italy, analyzed pharmaceutical usage before and up to three years after various bariatric surgeries. It found significant reductions in prescriptions for glucose-lowering, antihypertensive, and lipid-lowering drugs postoperatively, with variations according to surgery type.

Background

Metabolic and bariatric surgery is the most effective long-term treatment for obesity, leading to sustained weight loss and improvements in cardiometabolic comorbidities. Procedures are classified as restrictive (e.g., laparoscopic sleeve gastrectomy, adjustable gastric banding) or malabsorptive (e.g., gastric bypass). These surgeries not only reduce weight but also improve control of diabetes, hypertension, and dyslipidemia, often reducing the need for related medications. Prior studies on drug discontinuation post-surgery have been limited geographically and by data sources, prompting this large-scale analysis in a European population.

Data Highlights

Key Findings

• Bariatric surgery leads to marked decreases in the use of glucose-lowering, antihypertensive, and lipid-lowering medications within three years postoperatively.
• Malabsorptive procedures (gastric bypass) tend to show slightly higher rates of medication discontinuation compared to restrictive procedures (sleeve gastrectomy, gastric banding).
• Hormonal changes induced by different surgical techniques may contribute to variations in metabolic outcomes and drug use reduction.
• Use of proton pump inhibitors and antidepressants showed variable trends post-surgery, indicating the need for individualized patient monitoring.
• The study utilized comprehensive healthcare databases covering nearly 10 million residents, ensuring robust population-level insights.

Clinical Implications

Clinicians can anticipate significant reductions in cardiometabolic medication requirements following bariatric surgery, particularly with malabsorptive techniques. This underscores the importance of close medication review and adjustment during postoperative care. Additionally, monitoring for other medication classes such as PPIs and antidepressants remains essential due to variable usage patterns.

Conclusion

This large population-based study confirms that bariatric surgery substantially reduces the need for key cardiometabolic drugs, with differences observed between surgical types. These findings support the role of metabolic surgery in improving medication burden and overall patient management.

References

1. International Federation for the Surgery of Obesity and Metabolic Diseases 2018 -- Bariatric Surgery Volume
2. Lombardy Healthcare Utilization Databases -- Pharmacoepidemiological Studies